Pertussis

This early-stage trial is testing a new vaccine that combines protection against several serious childhood diseases: diphtheria, tetanus, whooping cough, meningitis, and Hib. The study involves 260 children aged 2 months to 6 years to check the vaccine's safety and immune respons…

This study tests a combination of two antibiotics, aztreonam and avibactam, in newborns and infants up to 9 months old who have serious infections caused by gram-negative bacteria. The trial has two parts: one to see how a single dose moves through the body, and another to test m…

This study tests whether adding a second antibiotic (fosfomycin) to the standard antibiotic (ceftazidime) helps people with severe gram-negative infections recover faster. About 100 hospitalized adults will be randomly assigned to get either the combo or the standard drug plus a …

This phase 3 trial will give a single dose of the dTpa vaccine (Boostrix) to 95 healthy Japanese pregnant women between 27 and 37 weeks of pregnancy. The goal is to see if the vaccine triggers strong immunity in the mothers and passes protective antibodies to their babies at birt…

This study is looking at whether it's safe and effective to give the Tdap vaccine (for whooping cough) and the RSV vaccine at the same doctor's visit during pregnancy, or if they should be given separately. The researchers will recruit 60 healthy pregnant individuals and randomly…

This study tests whether a web-based educational program can improve pregnant women's knowledge about influenza and Tdap vaccines and increase their intention to get vaccinated. Researchers will compare the program to standard antenatal care in 351 pregnant women in Malaysia. Par…

This study will test 10,000 people in Cambodia for 57 different infectious diseases, including dengue, flu, and malaria. Researchers want to understand how these diseases spread and who is at risk. The goal is to give local health authorities the information they need to create b…

This study aims to create a safe, controlled human infection model for whooping cough. Healthy adults aged 18-50 will receive a nasal dose of the bacteria to cause a mild infection. Researchers will monitor symptoms and test nasal samples to find the best dose that infects most p…

This study observes 600 patients in Korea who receive Zavicefta for complicated abdominal or urinary tract infections or hospital-acquired pneumonia. Researchers track side effects and how well the drug works. It is required by Korean regulators to ensure the drug's safety after …